Mohit Sachdeva

Title: Mohit Sachdeva: Innovator in Adaptive Cell Immunotherapy

Introduction

Mohit Sachdeva is a prominent inventor based in New York, NY (US). He has made significant contributions to the field of adaptive cell immunotherapy, focusing on improving therapeutic outcomes for patients.

Latest Patents

Mohit Sachdeva holds a patent for "Targeted gene integration of CRS inhibitor genes for improved immune cells therapy." This invention addresses the challenges associated with cytokine release syndrome during cell therapy. It involves the genetic insertion of exogenous coding sequences into genetically engineered immune cells, enhancing their safety and therapeutic potential. The method utilizes soluble human polypeptides controlled by endogenous gene promoters that respond to immune cell activation, allowing for the production of safer immune primary cells.

Career Highlights

Mohit is currently associated with Cellectis, a company known for its innovative approaches in the field of gene editing and immunotherapy. His work has been instrumental in advancing the understanding and application of genetic engineering in immune cell therapy.

Collaborations

Mohit collaborates with notable professionals in his field, including Brian Busser and Philippe Duchateau. Their combined expertise contributes to the ongoing research and development of cutting-edge therapies.

Conclusion

Mohit Sachdeva's innovative work in adaptive cell immunotherapy exemplifies the potential of genetic engineering to enhance patient care. His contributions are paving the way for safer and more effective treatments in the medical field.